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Abstract: In this work we report on the synthesis and characterization of magnetic nanoparticles of
two distinct origins, one inorganic (MNPs) and the other biomimetic (BMNPs), the latter based on a
process of bacterial synthesis. Each of these two kinds of particles has its own advantages when used
separately with biomedical purposes. Thus, BMNPs present an isoelectric point below neutrality
(around pH 4.4), while MNPs show a zero-zeta potential at pH 7, and appear to be excellent agents for
magnetic hyperthermia. This means that the biomimetic particles are better suited to be loaded with
drug molecules positively charged at neutral pH (notably, doxorubicin, for instance) and releasing it
at the acidic tumor environment. In turn, MNPs may provide their transport capabilities under a
magnetic field. In this study it is proposed to use a mixture of both kinds of particles at two different
concentrations, trying to get the best from each of them. We study which mixture performs better from
different points of view, like stability and magnetic hyperthermia response, while keeping suitable
drug transport capabilities. This composite system is proposed as a close to ideal drug vehicle with
added enhanced hyperthermia response.
Keywords: biomimetic magnetite; drug delivery; magnetic hyperthermia; magnetite; MamC;
nanoparticles stability
1. Introduction
In spite of the certainly wide variety of magnetic nanoparticles (MNPs) with different geometries,
compositions and functionalizations [1–8] that have become available in recent years, and of the number
of applications that have been devised for them [1,9–12], when the goal is to provide a nanocarrier
suitable for targeted chemotherapy, there is still room for progress. On one hand, the methods for
obtaining MNPs need to be more cost- and time-effective, eco-friendly, and scalable. On the other,
the nanoparticles themselves should be improved in terms of maximizing the magnetic moment per
particle and providing novel surface properties while exploring their potential as hyperthermia agents
that would allow them to combine therapies in the near future.
In this context, cancer is one of the fields of application where magnetic nanoparticles certainly
appear as most promising [12–18]. Aside of drug delivery, whereby functionalized magnetic
nanoparticles are loaded with the chosen drug and some targeting molecule, such an antibody,
driven to the site of action, maintained there by continuous magnetic fields and eventually set
for delivery by some external action, magnetic hyperthermia appears as a realistic application of
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MNPs [19–27]. For that purpose, MNPs are dispersed at a suitable concentration in an aqueous
solution and located in the target place for action. There, they are subjected to an alternating magnetic
field (with induction of tens mT and frequency of several hundred kHz). Subsequently, the magnetic
nanoparticles increase the temperature of the microenvironment in which they are immersed inducing
apoptosis of the tumor cells, usually more sensitive to temperature increase compared to healthy
cells [28–30].
MNPs are generally produced either by the co-precipitation of iron salts in basic aqueous
media possibly stabilized by biocompatible surfactants/polymers or by the thermal decomposition
of organometallic precursors in high-boiling nonpolar organic solvents at elevated temperatures
(200–360 ◦C), allowing a great control of the size of the MNPs, their monodispersity and uniformity [31].
However, these methods have some drawbacks mainly derived from the high temperatures used,
organic solvents or poor solubility of the nanoparticles in water.
Many of these drawbacks are overcome in biomimetic MNPs (BMNPs). These are produced by
the mediation of magnetosome membrane-associated proteins (MAPs) from magnetotactic bacteria,
and in vitro experiments have been demonstrated to control the size (and thus the magnetic moment
per particle), shape, and surface properties of the nanoparticles [32,33]. BMNPs production can
be scaled up in vitro in eco-friendly, cost-effective magnetite precipitation experiments run at room
temperature and 1 atm total pressure by the simple addition of the recombinant protein. Promising
BMNPs have been obtained by the mediation of MamC protein from Magnetococcus marinus MC-1,
since these BMNPs are (i) superparamagnetic at room and body temperature while they present a
saturation magnetization of 61 emu/g (at 500 Oe and 25 ◦C); (ii) are larger than most commercial MNPs
and/or other biomimetic magnetites, although still single magnetic domain, showing higher blocking
temperature and slower magnetization increase, and thus, larger magnetic moment per particle; (iii)
contain up to 4.5 wt% of MamC, which provides functional groups allowing for functionalization;
and (iv) adopt the isoelectric point of MamC (pHiep 4.4), and are strongly negatively charged
at physiological pH (pH 7.4); this property allows the coupling and release of molecules to be
pH-dependent. Thus, at physiological pHs, they bind to positively charged molecules (such as
doxorubicin, DOXO hereafter) through electrostatic interactions, which are weaker at acidic pHs (such
as those found in tumor microenvironments), allowing the release of the adsorbed molecules, and
(v); they are fully cytocompatible and hemocompatible, but when they are coupled with DOXO they
display dose-dependent cytotoxicity [33].
Recall that single-domain magnetic nanoparticles are characterized by a spin configuration such
that in the absence of an external magnetic field, all spins are oriented parallel to each other and parallel
or antiparallel to a crystallographic direction, called the easy (or anisotropy) axis [34–36], so that each
particle is characterized by a large magnetic moment. Let us imagine for the moment that the particles
are immobile, fixed in a non-magnetic matrix, with their easy axes oriented randomly. At very low
temperature (or at very high frequencies of the external magnetic field, if this is non-stationary), the
transition between the two orientations along the easy axes can only be achieved by the application of
sufficiently large external magnetic field, so that the magnetization-H curve will take the form of a
square hysteresis cycle, according to the Stoner-Wohlfarth model [35,37]. As temperature rises above
0 K, the transition between the two orientations can be thermally activated, and the coercivity tends
to be reduced, eventually making hysteresis negligible. The same effect will be observed when the
field frequency or the particle size is very low, since the coercive field HC is related to the anisotropy
field Hk (in turn related to Keff, the effective magnetic anisotropy constant of the particles, and their
saturation magnetization MS as Hk = 2 Keff /µ0MS) by [35]:











Pharmaceutics 2019, 11, 273 3 of 16
where kBT is the thermal energy, V is the particle volume (or, in the case of coated particles, the volume
of the magnetizable core), µ0 is the vacuum magnetic permeability, H0 is the field amplitude, f is the
field frequency, and the characteristic time τ0 depends on such quantities as temperature, saturation
magnetization or anisotropy constant. It will be assumed to be a constant in the range of 10−10–10−9 s.
If it is admitted that it suffices with HC being 0.01–0.1Hk to have reversible cycles and absence of
hysteresis, then the combination of H0, f, V, and MS must be such that κ = 0.97–0.75.
An approximate approach to the general solution of the problem, not using models based on
the Stoner-Wohlfarth one is the so-called linear-response theory, where, keeping the assumption of
immobile particles, it is found that the hysteresis cycle has its origin in the Néel-Brown relaxation,
characterized by a relaxation time τN, which is a measure of the time taken by the system to return
to equilibrium after application of a step magnetic field, or half the time needed for spontaneous
inversion of magnetic moment orientation [38–40]. It is given by:






This brings about a delay between magnetization and field, or an imaginary component of the
magnetic susceptibility, and manifests again in a finite area hysteresis cycle, as long as the frequency of
the field remains in the vicinity of 1/τN. This approach is only strictly valid for low applied magnetic
field strength or highly anisotropic particles.
For hyperthermia applications, the particles are typically dispersed in an aqueous solution, and
hence they can rotate under field inversions so that viscous friction is an additional source of phase
delay between magnetization and external field, and hence, an additional relaxation contribution to





where η is the viscosity of the medium, and VH its hydrodynamic volume (including, if any, that of the
coating layer) [19,41,42]. Taking the value ofKeff equal to 25 kJ/m3 for magnetite, the Brownian relaxation
times for biomimetic (~35 nm in diameter, reported below) and purely inorganic particles (~28 nm) are,
respectively, 14.4 µs, and 7.4 µs, and orders of magnitude higher in the case of magnetization reversal.
This means that for the particle sizes and frequencies involved, the magnetic moment is frozen in the
particle and the only heating source is friction, according to the linear response model. Considerations
on the validity of the relaxation approach just described can be found in References [43–46]. In the
context of the linear response theory, if the alternating magnetic field has a frequency in the vicinity
of the reciprocal of the mentioned times (f in the order of 70 kHz and 135 kHz, respectively), the
imaginary component, χ”, of the complex magnetic susceptibility is maximum, and this is important,





Another important aspect, not always considered, regards the stability of the particles in the
suspension, compromised not only by the colloidal interactions but also by the magnetic dipolar
ones. Hence the need for properly controlling the stability, as the hyperthermia response degrades for
aggregated systems [22,47] or when the monodomain range is surpassed [36,48].
Experimentally, the quantity of interest is the so-called Specific Absorption Rate (SAR), or heat
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C being the volume heat capacity of the suspension, Vs its volume and dT/dt the rate of temperature
increase [28,39]. Typical SAR values are in the order of tens to hundreds of W/g. In order to perform a
comparison between different materials without the interference of the details of the specific device
used (very often lab-made), a quantity is defined as a measure of the magnetothermal performance of





with typical values in the order of 10−9 Hm2kg−1.
In this work, we explore the possibility of maximizing the hyperthermia effect (the rate of
temperature rise, in fact) by combining the two types of magnetic particles (BMNPs and MNPs),
differing in size and other properties. The goal of the present study is to provide a composition that
could be used in the future as a platform for combining drug delivery and hyperthermia. The former
particles, BMNPs, mediated by MamC have been chosen because of their demonstrated ability to
function as nano-transporters of drugs, being the nanoassembly stable at physiological pH while it
destabilizes releasing the drug under acidic pH values, which naturally occur in the tumor environment.
The second ones, MNPs, have been chosen because of their potential as hyperthermia agents [33]. By
mixing the two systems, we expect to deliver a system that, in the future may prove useful to combine
both treatments, i.e targeted chemotherapy plus targeted hyperthermia by using the same platform.
To the best of our knowledge, the hyperthermia of mixed systems has never been investigated, but
advantages are foreseen regarding the possibility of optimizing the response.
2. Experimental
2.1. BMNPs and MNPs Production
Details of the production process are given in Reference [32], and just a short account will be
provided here. The MamC gene (ABK44766.1, NCBI Database) was first amplified by the polymerase
chain reaction and cloned into pTrcHis-TOPO vector, and expressed in Escherichia coli TOP10 competent
cells, both from Life Technologies, Invitrogen, Grand Island, NY, USA. The cells were grown at 37 ◦C
in Luria-Bertani (LB) broth supplemented with 100 mg/mL of ampiciline. After 5-h contact with
isopropyl-β-d-thiogalactopyranoside (IPTG, Fisher BioReagents, Pittsburgh, PA, USA) the expression
of the recombinant MamC was induced. The cell pellet was resuspended in guanidinium lysis buffer
overnight. The lysate was centrifuged, and the supernatant loaded onto a HiTrap chelating HP column
(GE Healthcare, Chicago, IL, USA) equilibrated with Denaturing Binding Buffer (A). The protein eluate
was obtained with Denaturing Elution Buffer (B), and the final step was isolating the MamC protein by
successive dialyzations with buffers A and B. The isolated protein was stored at 4 ◦C until used in the
biomineralization process (all buffers were purchased from Sigma Aldrich, St. Louis, MO, USA).
The following step was the production of the MNPs and BMNPs (all reagents needed in this process
were purchased from Sigma-Aldrich, Madrid, Spain). Milli-Q water (Millipore, Barcelona, Spain) was
first deoxygenated by boiling it for 1 h and then cooling in an ice bath while bubbling nitrogen. The
water was immediately stored inside an anaerobic chamber (Coy Laboratory Products, Grass Lake, MI,
USA) with a 4% H2 in N2 atmosphere. The following solutions were prepared inside the chamber:
NaHCO3/Na2CO3 (0.15 M/0.15 M), FeCl3 (1 M), Fe(ClO4)2 (0.5 M), and NaOH (5 M). The precipitation of
inorganic magnetite (MNPs) was carried out as described in Reference [49], and consisted in mixing the
prepared solutions to the final concentrations of 3.5 mM/3.5 mM, 5.56 mM, and 2.78 mM, respectively,
at 25 ◦C and 1 atm. NaOH was added to reach a pH of 9. The biomimetic nanoparticles were obtained
by adding the purified MamC protein (at a final concentration of 10 µg/mL) to the solution used for
MNPs. In both cases, the solids were allowed to grow for 30 days, and magnetically decanted and
washed three times with deoxygenated water. The magnetic particles were kept in water inside the
Coy chamber until further use.
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2.2. Nanoparticle Characterization
The morphology and particle size of the synthesized nanocrystals were analyzed by Transmission
Electron Microscopy (TEM Philips Model CM20, Eindhoven, The Netherlands) equipped with an
energy dispersive X-ray spectrometer (EDAX). The size of the particles was measured by using ImageJ
1.47 software, and size distribution curves and ANOVA statistical analyses were determined from
measurements performed on 1000 particles. Averages were considered significantly different if p <
0.05. Powder x-ray diffraction (XRD) analysis was carried out on lyophilized samples with an Xpert
Pro X-ray diffractometer (PANalytical; Almelo, The Netherlands) using Cu Kα radiation, with the scan
range set from 20–60◦ in 2θ (0.01◦/step; 3 s per step). Electrophoretic mobility measurements were
carried out in a Zetameter Nano-ZS (Malvern Instruments, Malvern, UK) at 25 ◦C, in suspensions
with 0.01% w/v solids concentration and constant ionic strength of 5 mM KNO3. For each suspension,
5 measurement runs were taken. Magnetization cycles and zero-field cooled field-cooled (ZFC-FC)
curves were obtained in an MPMS-XL SQUID magnetometer (Quantum Design, San Diego, CA,
USA). The stability of the samples was evaluated optically by measuring the time evolution of the
phase separation line between particles and medium: The samples were photographed at certain
intervals. Afterward, the height and volume of each phase were determined through image processing
and analyzed.
Magnetic hyperthermia experiments were carried out using an AC current generator with a
double four-turn coil made of water-cooled copper tube, 4 mm in inner diameter, with 800 mL/min flow
rate, comparable to other experimental hyperthermia devices [50]. Three frequencies, namely, 197 kHz,
236 kHz, and 280 kHz were selected, with a fixed magnetic field intensity of 18 kA/m, measured at the
center of the coil with a NanoScience Laboratories Ltd. Probe (Staffordshire, UK), with 10 µT resolution.
These were the combinations accessible with our measurement system, but are close to those used by
other authors [45,46,51]. The samples to be evaluated were placed in plastic Eppendorf tubes (1.5 mL
sample volume). Four kinds of dispersed systems were evaluated, namely those based on pure MNPs
or BMNPs, and mixtures containing 25% BMNPs + 75% MNPs (here referred to as 25 B + 75 M), and
60% BMNPs + 40% MNPs (60 B + 40 M). This selection was based on using a combination with a
predominance of inorganic MNPs and another one with a higher fraction of biomimetic particles in
order to estimate the relative contribution of each type of particles.
The SAR and ILP of the dispersions were obtained by measuring the rate of temperature increase
as a function of time [19,52], with an optical fiber thermometer (Optocon AG, Dresden, Germany),
and using Equations (6) and (7). Considering the rather low concentration of MNPs, the corrections
proposed by Gas and Miaskowski [51] in the calculation of the heat capacity of the suspension did not
appear necessary. All samples for hyperthermia were prepared with a solids concentration of 25 mg/mL.
Note that this concentration is higher than usual in hyperthermia applications (more in the range
of 1–10 mg/mL), but it was chosen with the aim of magnifying differences. At such concentrations,
magnetic or colloidal interactions might likely affect hyperthermia, as increased stability seems to
favor the temperature elevation, if the frequency of the magnetic field is selected in accordance with
the size of individual, non-aggregated particles. In fact, in a previous work [22], we found that the
hyperthermia response was improved if the suspensions were more stable, although the SAR of 20 nm
magnetite suspensions was constant up to 2% (v/v) (or about 100 mg/mL) concentration.
3. Results and Discussion
3.1. Particle Characterization
Figure 1B,D show representative TEM pictures of the two kinds of particles. Size histograms are
represented in Figure 1A,C, respectively. The mean (± S.D.) diameters obtained from the histograms
were 35 ± 11 nm for BMNPs and 18 ± 6 nm for the purely inorganic nanoparticles. Insets in the pictures
also show that the shape of both kinds of particles is rather polyhedral, with better homogeneity in the
biomimetic case.
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Figure 1. Dia eter histograms (A,C) and TE pictures (B,D) of bio i etic (B Ps) and purely
inorganic ( NPs) magnetic nanoparticles. The scale bar in B, D is 200 nm.
Figure 2 shows the XRD patterns of both samples. Note the good crystallinity in the two cases,
and the excellent coincidence with the magnetite reference pattern (JCPDS card No 19-0629), being the
main reflection for magnetite the 311 (d-spacing = 2.530 Å, for Cu Kα radiation, 2θ is 35.44 degrees).
The goethite diffraction lines are also superimposed in the figure, and only a low-angle peak seems
to correspond to this oxide. Using Scherrer’s formula [53], the crystallite size was obtained for both
samples from the half-intensity width of all the lines in the pattern, using specialized Rietveld software
(TOPAS 5.0, Bruker, Hamburg, Germany). Calculated crystallite sizes for MNPs vary between 13.0 and
18.3 nm, while those for BMNPs vary between 13.1 and 22.5 nm. Thus the calculated size from XRD
data for MNPs matches that measured from TEM images. However, this is not the case for BMNPs for
which we get smaller values than those measured with TEM. Recall that the crystallite size calculated
from XRD data is a measure of the size of coherent diffraction domains, which can be smaller than
the particle size if small discontinuities will make the domain lose such a coherency. It is true that
BMNPs could be polycrystals, but this is not what was found by High-Resolution TEM observations
of BMNPs in Reference [54]. No discontinuities in lattice fringes were observed, and therefore, the
polycrystallinity of BMNPs seems to be ruled out, at least for the majority of the BMNPs analyzed.
However, Garcia-Rubia et al. [33] suggested the incorporation of MamC in the outer layers of the
BMNPs crystals, that prevented the removal of the protein, and measured, in fact, that 5% of the total
mass of the BMNPs is MamC. The presence of the protein would, most probably, induce some defects
in the crystal structure, resulting in the loss of coherency in the diffraction. This is why, in BMNPs, the
crystal sizes calculated from XRD are lower than those measured in TEM images.
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Figure 2. The XRD diffraction patterns of purely inorganic (MNPs) and biomimetic magnetic
nanoparticles (BMNPs). The positions and intensities of crystallographically-pure magnetite are
labeled as M, and those of goethite as G.
The magnetization of the two kinds of particles and an example of one of the mixtures (25 B
+ 75 M, in fact the most stable mixture, as will be discussed below) is plotted in Figure 3 for two
temperatures, 5 K and 300 K. The detail in Figure 3 shows that some really low remnant magnetization
(about 20 emu/g at most), and coercivity can be measured at 5 K, with the interesting feature that this
is maximum for the mixed system. This can be ascribed to some degree of aggregation between the
two kinds of particles, as at the pH of the aqueous suspensions in which the mixtures were prepared
they are oppositely charged (detailed below), and electrostatic attraction cannot be ruled out. For
room temperature measurements, the magnetization shows no hysteresis, and the particles behave as
paramagnetic. This is characteristic of superparamagnetism, as mentioned. At room temperature, the
saturation (mass) magnetization reaches 66 emu/g in the case of MNPs and 25 B + 75 M, and 55 emu/g
in the case of BMNPs. Considering the dilution effect of the coating caused by the incorporation of
MamC [33], the corrected value of saturation magnetization is 61 emu/g for BMNPs, and 70 emu/g for
25 B + 75 M.
Zero-field cooling-field cooling (ZFC-FC) curves at 500 Oe (39.8 kA/m) (see Figure 4) show
that the blocking temperature (maximum in the ZFC cooling curve, the lower branch in each case,
corresponding to the rounded appearance of the curve [55]) is 103 K for MNPs, 145 K for BMNPs and
180 K for 25 B + 75 M, and that at temperatures higher than blocking temperature, (including 300
K and above in all cases), these particles will behave as non-magnetic in the absence of an external
magnetic field, confirming the superparamagnetic nature of the two kinds of particles. This prevents
magnetic aggregation, a very favorable feature of the systems investigated.
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However, once an external magnetic field is applied, the nanoparticles will respond efficiently.
From these results, it can be inferred that either the bare MNPs and BMNPs, or their mixtures, appear
as ideal candidates for the purpose of hyperthermia, drug delivery or combinations thereof.
3.2. Zeta Potential
For the purpose of drug loading and delivery, the ability of the nanoparticles to be coupled to
molecules forming stable nanoassemblies at physiological pH and to release the drug at the precise time,
as well as the stability, drug-particle or cell membrane-particle interactions, among other properties, are
strongly determined by the surface charge, or, alternatively, by the zeta potential ζ, of the particles when
dispersed. Calculations of the zeta potential were done from the measurements of the electrophoretic
mobility of the particles BMNPs and MNPs by means of O’Brien and White’s general theory [56]. As
one can see in Figure 5, the isoelectric point (pHiep or pH of zero ζ) of MNPs was obtained at pH 7.0,
while for BMNPs it was 4.4. This zeta potential plot reveals significant differences between both types
of nanoparticles. They are positively charged at low pH values and negatively charged at high pH,
but BMNPs change from positive to negative at quite a different pH: This suggests that the MamC
protein is affecting the surface of the particles, and it is probably located mainly at the interface. In
fact, the investigations by Nudelman et al. [57], and other authors [54,58] on the biomineralization
mechanism induced by this protein demonstrate that the particularity of MamC is the template effect
for magnetite nucleation and growth that this protein exerts. The two negatively charged amino acids
Asp70 and Glu66, located in MamC loop, are separated by about 8 Å, and this distance can match
the disposition of iron cations on (100), (110), and (111) faces. Therefore, the crystal could grow in
an orderly manner, first from the Fe cations available in solution and then, since the amount of Fe in
solution is limited, at the expense of the release of the Fe cations adsorbed in other negatively charged
moieties of MamC. Since the process of nucleation is kinetically favored by this template effect, it is
precisely those exposed amino acids that act as nucleation sites. Therefore, the restricted number of
nucleation sites in the presence of MamC compared to the process of homogeneous nucleation from
the bulk solution allows the formation of larger crystals in the former. Moreover, since (100), (110),
and (111) faces show up in the final morphology of the BMNPs [57], it can be concluded that, while
exerting this template effect for the nucleation, the protein prevents the growth of the crystal on these
specific directions.
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at such pH values, resulting in a stable nanoassembly. On the contrary, when they eventually reach the
tumor (acidic pH values), the drug releases from the BMNPs, as the charge of the latter at acidic pH
values is nearly zero [33]. That makes the BMNPs better drug nanocarriers compared to MNPs, as
in the former the release of the drug can be controlled by an external factor, as it is a change in the
environmental pH value. This feature is absent in MNPs, as their charge is positive anywhere below
pH 7.
3.3. Stability
Like in many other applications, the use of magnetic nanoparticles in health applications requires
to ensure sufficient stability. Previous results from our laboratory demonstrated that, specifically when
it comes to hyperthermia applications, the stability, either electrostatically or polymerically achieved,
is an essential factor for optimizing the performance of the system [22]. Hence, in this part of the
study, we focus on the possibility of improving hyperthermia by favoring stability. It must be recalled
that superparamagnetic nanoparticles interact attractively through van der Waals interactions and
dipolar magnetic ones (if remanence is not negligible, which is not our case at room temperature,
see Figure 3). Furthermore, the repulsive interactions due to the surface charge will be very low at
physiological pH values in the case of MNPs, and larger in the case of BMNPs (Figure 5). In addition,
steric hindrance could contribute to the stability of the biomimetic nanoparticles through the presence
of surface MamC molecules. In order to confirm this possibility, we evaluated the sedimentation
behavior vs. time of the samples (pure end members and mixtures of BMNPs and MNPs). The time
evolution of the boundary between sedimented volume (height h) and clear supernatant, relative to
the initial height h0, will be used as a simple test of stability. Data are plotted in Figure 6. Surprisingly,
it can be observed that, although the stability of bare MNPs is lower than that of BMNPs, as expected
from the steric and electrostatic repulsions due to the MamC coating, adding BMNPs to the former
at a relative concentration of 25/75 (25 B + 75 M) brings about a measurable increase of stability.
This may be the result of a compromise between the smaller size of MNPs favoring stability and the
addition of the protective coating represented by the BMNPs. As a result, an ideal system with a mixed
composition emerges.
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Figure 6. Height of the sedimented volume relative to its initial value as a function of time for MNPs
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3.4. Performance in Hyperthermia
As a novel field of application of the two kinds of particles and their mixtures, we consider to
what extent they are efficient magnetic hyperthermia agents. Figure 7 shows the time evolution of the
temperature of the suspensions of MNPs, BMNPs and the two mixtures 25 B + 75 M and 60 B + 40 M
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under the influence of an alternating magnetic field at the indicated frequencies and a fixed magnetic
field strength of 18 kA/m. All types of nanoparticles are able to raise the temperature, the fastest
rise occurring for the highest frequency. This effect is particularly visible at longer times. The rate
of temperature increase is maximum (~34 ◦C/min) in mixture 25 B + 75 M and minimum in BMNPs
(~17 ◦C/min) at the highest frequency. It appears that inorganic MNPs are better hyperthermia agents
than BMNPs. This justifies their presence in the mixtures under study. They make it possible to design
a composition of nanoparticles that (i) can be guided to the target by the application of an external
magnetic field; (ii) behave as suitable drug nanocarriers, stable at physiological pH values and from
which the drug release is dependent of an external stimuli, e.g., acidic tumor environment (these are
the BMNPs); (iii) produce a fast increase of the temperature of the system upon the application of an
external magnetic field (these are the MNPs).
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In fact, maximum SAR (up to 96.2 W/g) and ILP (1.26 nHm2kg−1) values were obtained for the 25
B + 75 M sample, followed by MNPs, 60 B + 40 M and, finally, BMNPs (Figure 8, Table 1). The lower
heating induced by BMNPs is probably related to the larger size of the particles and to the presence
of MamC attached to their surface, which probably hinders the rotation of the nanoparticles. The
increased SAR and ILP values obtained for the 25 B + 75 M samples is promoted by stability, as single
particles with close-to-spherical symmetry rotate under the action of the field less impeded than in the
case of aggregated particles. In addition, it is likely that the field frequencies used are closer to those of
maximum phase lag between magnetization and field, for the MNPs than for the BMNPs, so the latter
would play here the role of favoring stability.
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25 B + 75 M
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280 75 ± 8 0.82 ± 0.09 27.5 ± 0.2
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high saturation magnetization in the presence of an ext rnal magnetic field, be ng thus able to be
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in the isoelectric point (iep) of th nanoparticles induced by MamC (iep = 4.4). In contrast, MNPs are
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of the BMNPs. However, while potentially good nanotransporters, BMNPs are not as good agents f r
hyperthermia as MNPs. Theref re, the present study offers a compo ition of nanoparticles, nam ly,
Pharmaceutics 2019, 11, 273 13 of 16
25% BMNPs + 75% MNPs that, while having the maximum hyperthermia response, likely related to
improved stability of the sample, is also suitable as a drug nanocarrier designed to deliver the drug in
response to changes in the environmental pH. Therefore, the combination of inorganic and biomimetic
nanoparticles potentially allows combined targeted chemotherapy and targeted hyperthermia.
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